The Preventive Cardiology Checklist for Women

This wing has covered a great deal, and a woman should not have to hold all of it in her head.

The Mechanism

Cardiovascular risk assessment exists on paper as a systematic process, one that starts with objective numbers, incorporates medical history, and produces an estimate that guides prevention decisions. In practice, the process has gaps, and for women those gaps fall in consistent places.

The numbers tend to get measured, eventually. Blood pressure is checked at most clinical visits. Lipid panels are ordered periodically. Glucose or HbA1c appears on routine metabolic panels. These measurements are imperfect, they come at variable intervals, and the interpretation is not always applied to a prevention decision, but the numbers are more likely to exist in a chart than the history is.

The sex-specific history is what falls through. Standard cardiovascular intake was designed primarily around a male risk template, and it shows. Forms ask about hypertension, diabetes, and smoking. They do not reliably ask about preeclampsia, gestational diabetes, preterm birth, early menopause, migraine with aura, or autoimmune disease. Yet all of these are recognized risk enhancers in the 2019 ACC/AHA Primary Prevention Guideline and the 2022 American Heart Association Scientific Statement on Cardiovascular Disease in Women (Vogel et al., Circulation, 2022). The history that most specifically characterizes a woman’s cardiovascular risk is the history that most consistently fails to enter her record.

This is not a subtle problem. The AHA 2022 statement noted explicitly that adverse pregnancy outcomes, including preeclampsia and gestational diabetes, are underused in clinical cardiovascular risk assessment. A survey by Parikh et al. in Hypertension (2021) found that fewer than half of cardiologists and internists routinely asked about pregnancy complications during cardiovascular evaluations. The practical implication is that a woman cannot rely on being asked. She has to supply the history herself if it is going to influence her care.

There is also a structural issue with the primary risk calculation tool. The Pooled Cohort Equations, which have been the standard 10-year ASCVD risk calculator in the United States since the 2013 ACC/AHA guidelines, incorporate age, sex, race, total cholesterol, HDL, systolic blood pressure, blood pressure treatment status, diabetes, and smoking. Reproductive history is absent from the equation. When a clinician runs those numbers, the estimate returned is mathematically blind to a woman’s prior preeclampsia, gestational diabetes, or early menopause. The only way those factors enter the risk conversation is if someone supplies them as clinical context on top of the calculated number.

What the Evidence Shows

The case for each component of the checklist is built on specific findings across populations large enough to be clinically meaningful.

Blood pressure is the clearest entry point. Among women, hypertension is the single largest modifiable risk factor for cardiovascular disease and stroke. A meta-analysis of individual participant data by the NCD Risk Factor Collaboration (Lancet, 2021), encompassing nearly 20 million adults, documented the global burden of hypertension and its direct relationship to cardiovascular mortality across sexes. The SPRINT trial established that intensive blood pressure targets below 130/80 mmHg reduce major cardiovascular events, and the 2017 ACC/AHA guideline adopted those targets. For women in the menopause transition, blood pressure can shift meaningfully over one to two years, making serial measurement more informative than any single clinic reading. Home blood pressure monitoring, averaging readings over at least five to seven days under consistent conditions, is more representative of true cardiovascular risk than office values taken in an acute setting.

Lipid assessment is more layered than a standard panel suggests. LDL cholesterol is the most widely used metric, but ApoB is a more direct measure of atherogenic particle number. In women with insulin resistance, metabolic syndrome, or elevated triglycerides, ApoB diverges from LDL in clinically significant ways: LDL can appear reassuringly normal while the particle count driving atherosclerosis is elevated. The 2022 ACC Expert Consensus Decision Pathway (Lloyd-Jones et al., Journal of the American College of Cardiology, 2022) recommends ApoB as a secondary measurement when risk-based treatment decisions are uncertain. Lipoprotein(a), or Lp(a), is a genetically determined, independent risk factor for cardiovascular disease and aortic stenosis that is not captured by standard lipid panels. The European Atherosclerosis Society has recommended at least one lifetime measurement for most adults. American guidelines have moved in the same direction. For women specifically, Lp(a) elevation can interact with the post-menopausal lipid shift in ways that amplify overall atherogenic burden; a woman with modest LDL elevation and elevated Lp(a) is in a meaningfully different risk category than one whose LDL is the only concern.

Blood glucose and HbA1c track metabolic risk, and for women the trajectory across the menopause transition is particularly important. A history of gestational diabetes raises the lifetime risk of type 2 diabetes, with Bellamy et al. (Lancet, 2009) finding a sevenfold increase in subsequent diabetes risk among affected women. Women with that history need more frequent glucose tracking than standard intervals, and those results need to feed explicitly into cardiovascular risk conversations rather than being managed in isolation by a primary care provider. The connection between metabolic health and cardiovascular risk is direct, not tangential, and for women with gestational diabetes in their history it is a connection that warrants close attention.

On the history side, the evidence base for each component is summarized elsewhere in this wing: preeclampsia approximately doubling long-term cardiovascular risk (Bellamy et al., Lancet, 2007); early menopause before forty-five raising cardiovascular risk by approximately 50% (Gong et al., European Heart Journal, 2022); migraine with aura approximately doubling ischemic stroke risk in women (Kurth et al., Neurology, 2012); and autoimmune diseases including rheumatoid arthritis raising cardiovascular risk by roughly 50% independently of traditional risk factors (Peters et al., Annals of the Rheumatic Diseases, 2010). These are not rare findings among women presenting for cardiovascular care; they are common, they change the risk picture materially, and they regularly go unrecorded.

The question of frequency deserves a specific answer. There is no single guideline-specified interval for all of these checks simultaneously. Blood pressure should be measured at every clinical encounter. A fasting lipid panel is indicated at least once in early adulthood, with frequency thereafter determined by results and overall risk. Glucose or HbA1c should be checked periodically, with more frequent monitoring in women with gestational diabetes history, metabolic syndrome, or entering the menopause transition. The principle is not a fixed schedule but a commitment to not letting years pass without knowing where these numbers stand.

Cardiovascular Imaging: When the Numbers Alone Are Not Enough

For a woman whose numbers and history place her in a clinical grey zone, a 10-year ASCVD risk of 7 to 15 percent, a family history that concerns her clinician but does not clearly move the treatment decision, or a preeclampsia history being weighed but not yet acted on, cardiovascular imaging can shift that decision from uncertain to clear. These tools do not replace the checklist; they resolve it when the checklist alone cannot.

Coronary artery calcium scoring is the most evidence-supported tool for this purpose. CAC measures calcium burden in the coronary arteries using a low-radiation CT scan without contrast, taking approximately 10 minutes. The score stratifies risk on a continuous scale: a CAC of zero in an asymptomatic woman over 55 is associated with a very low 10-year cardiovascular event rate, MESA data showed fewer than 0.4 events per 100 patient-years in the zero-CAC group (Blaha et al., JACC Cardiovascular Imaging, 2017). A CAC score above 100 shifts the risk estimate upward substantially, typically moving a woman from the uncertain range into a range where statin therapy and more aggressive blood pressure management are clearly warranted by guideline criteria.

Sex-specific interpretation of CAC matters. MESA data documented that women accumulate coronary calcium approximately 10 years later than men; the median CAC in a 55-year-old woman is near zero, while the same score in a 65-year-old woman with a preeclampsia history warrants more careful interpretation than zero in a low-risk woman at 55. The 2019 ACC/AHA Primary Prevention Guideline identifies CAC as the preferred risk-refinement tool when treatment decisions remain uncertain after standard risk assessment, and explicitly recommends it for patients in the borderline (5 to 7.5 percent) or intermediate (7.5 to 20 percent) risk ranges.

Carotid intima-media thickness (CIMT) uses ultrasound to assess arterial wall thickness directly, a measure of subclinical atherosclerosis that requires no radiation. The 2010 ASE/ACCF Scientific Statement endorsed CIMT as a risk stratification tool in intermediate-risk individuals. CIMT above the 75th percentile for age and sex, or a discrete plaque on carotid imaging, reclassifies risk upward and predicts first cardiovascular events independently of the Framingham risk score in ARIC cohort analyses. CIMT adds information about non-coronary atherosclerosis that CAC does not capture and is an appropriate alternative for women who cannot or prefer not to undergo CT scanning.

The ankle-brachial index (ABI) is the simplest whole-body atherosclerosis indicator available in an office setting. A ratio of ankle to arm systolic pressure below 0.9 identifies peripheral arterial disease and approximately doubles cardiovascular event risk. For women who have completed the checklist and still require risk clarification without imaging, ABI is a non-invasive, radiation-free option that can be measured with a handheld Doppler and standard blood pressure cuffs.

None of these tools is appropriate for universal population screening. They are risk-refinement tools for women who have completed the numbers-and-history evaluation and find themselves in the clinical uncertainty zone where a treatment decision genuinely could go either way.

The Questions to Bring

Written questions are not a confrontational posture; they are a recall aid and an accountability mechanism. A short clinical visit produces a lot of information in both directions, and questions that are not written down tend not to get asked. Three questions cover the essentials for most women.

The first is about overall risk: what is my 10-year cardiovascular risk estimate and does it incorporate my sex-specific history? This question forces the risk number into the conversation and flags whether the calculation was informed by reproductive history or was based solely on the standard Pooled Cohort Equations inputs.

The second is about prevention adequacy: given my risk, am I receiving appropriate prevention? This translates the risk number into a question about action. A woman whose risk is 12 percent on the calculator, but who has a preeclampsia history that shifts her true risk higher, may be in the borderline range where a statin or blood pressure intervention is warranted. The question makes the clinical decision explicit rather than leaving it implicit.

The third applies if symptoms are present: has my heart been ruled out as the cause of these symptoms, and if so, by what means? Women’s cardiac symptoms are more frequently atypical, including fatigue, dyspnea, nausea, and jaw or arm discomfort without classic chest pain, and are more frequently attributed to non-cardiac causes. The question serves as a direct prompt to address that diagnostic gap.

What to Do This Week

1. Write your key numbers on one page, including the most recent values for blood pressure (ideally with home readings over at least five consecutive days), total cholesterol, LDL, ApoB if measured, Lp(a) if measured, fasting glucose or HbA1c, and your most recent overall cardiovascular risk estimate if one has been calculated.

2. Add your sex-specific history to the same page: any hypertensive disorder of pregnancy, gestational diabetes, preterm birth, small-for-gestational-age delivery, the age menopause occurred, any autoimmune disease, migraine with aura, PCOS, and family history of premature heart disease.

3. Write the three questions listed above on the same page, or use them as a template for the questions specific to your situation.

4. Track the numbers over time rather than treating any one result as conclusive. Set a calendar reminder to update the page once a year, after any routine blood work.

5. If you have symptoms that could be cardiac, including unusual fatigue, shortness of breath with exertion, chest discomfort, palpitations, or jaw or arm pain, add the symptom question and make the appointment specifically to address it rather than listing it at the end of an unrelated visit.

The preventive cardiology checklist is the whole return protocol on one page: know your numbers, carry your history, ask the questions. A woman who brings that page to her clinician has done the single most reliable thing she can to ensure her heart is assessed completely, and that the assessment is based on her actual risk picture rather than the abbreviated version the intake form captured.

The Women’s Signal Check is fifteen questions mapping the female cardiovascular risk pattern, including reproductive history, microvascular signals, and the factors standard risk calculators do not capture. It produces a specific starting point for your next clinical conversation.